Actively Recruiting
CD4^LVFOXP3 in Participants With IPEX
Led by Bacchetta, Rosa, MD · Updated on 2025-05-22
30
Participants Needed
1
Research Sites
775 weeks
Total Duration
On this page
Sponsors
B
Bacchetta, Rosa, MD
Lead Sponsor
C
California Institute for Regenerative Medicine (CIRM)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This first-in-human, Phase 1 clinical trial will test the feasibility of the manufacturing and the safety of the administration of CD4\^LVFOXP3 in up to 30 evaluable human participants with IPEX and evaluate the impact of the CD4\^LVFOXP3 infusion on the disease.
CONDITIONS
Official Title
CD4^LVFOXP3 in Participants With IPEX
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Body weight greater than 8 kg, unless able to tolerate leukapheresis
- FOXP3 gene mutation
- History of progressive IPEX symptoms requiring immune suppressive medication, with or without current immunosuppression
- Uncontrolled IPEX disease but unable to tolerate immune suppressive medication
- Recurrent IPEX symptoms requiring immune suppressive medications after prior allogeneic blood stem cell transplantation
- Performance rating of at least 50% on Lansky/Karnofsky Scale
- Organ and marrow function within acceptable limits
- No ongoing infections
- Ability to consent if an adult
You will not qualify if you...
- Medical instability
- Life expectancy less than 6 months
- Inability to meet steroid dosing limits
- Eligible and willing for HLA matched sibling or unrelated donor blood stem cell transplant
- Unrelated or comorbid diseases
- Allergy to any study medication, product, or intervention
- Currently receiving another experimental treatment
- History of malignancy unless disease-free for at least 2 years, except non-melanoma skin cancer or carcinoma in situ
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Lucile Packard Children's Hospital
Palo Alto, California, United States, 94305
Actively Recruiting
Research Team
R
Rosa Bacchetta, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here